46 results about "Vaginal gel" patented technology

The endometriosis treatment protocol provides for administering to a female patient in need of treatment for endometriosis a pharmaceutical composition in a form suitable for vaginal or rectal delivery having a pharmaceutically effective amount of an aromatase inhibitor, which may be either a steroid or non-steroidal. The pharmaceutical composition may be formed as a vaginal suppository, a rectal suppository, a vaginal gel, a rectal gel, a vaginal cream or a rectal cream. The pharmaceutical composition may optionally have pharmaceutically effective amounts of progesterone and calcitriol, and may be administered in combination with an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition comprises an aromatase inhibitor administered vaginally or rectally and is administered in combination with oral calcitriol and the oral COX-2 inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.

A matrine vagina gel is prepared from matrine (5-50 wt. portions) Kapomu (5-50), glycerine (25-500) and distilled water (400-4500). Its advantages are high curative effect, long stay time, no damage to vagina and no pollution to clothes.

The invention discloses an acidic buffering sterilization gel for vagina gynaecologically. The gel consists of the following substances in parts by weight: 0.2-0.5 part of bactericide, 12-12.5 parts of glycerol, 83-84 parts of water, 1-1.5 parts of Carbomer, 1.5-2 parts of polycarbophil, 0.2-0.3 part of triethanolamine, 0.01-0.03 part of vitamin E, and 0.01-0.03 part of mint. The acidic bufferingsterilization gel has the advantages that: pathogenic bacteria can be quickly and effectively killed, inflammatory symptoms can be quickly and effectively relieved, normal pH value of the vagina is maintained, elasticity of the inner wall in the vagina can be kept, wetness of the vagina is maintained, and drug tolerance and drug resistance do not generate.

The invention discloses a vaginal gel which is prepared from the following raw materials: Nifuratel and Nysfungin 300-600 parts, glycerin 200-400 parts, gel base material 100-500 parts. The preparing process consists of steps of abrading homogeneously, charging charging base materials into turbid liquor and stirring homogeneously, and adjusting pH to be 6-7.

A vaginal gel tablet for treating gynopathy contains hydrophilic gel material (1-40%) and effevescent disintegrant or superdisintegrant (20-50%). It advantages are quickly taking its effect and durable action.

The invention relates to a chlorhexidine and oligochitosan-containing pharmaceutical composition, wherein the mass proportion of the chlorhexidine to oligochitosan is (0.1-1):1, the chlorhexidine comprises chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride or chlorhexidine citrate, and the molecular weight of the oligochitosan is less than 5,000. The invention further relates to an application of the pharmaceutical composition in preparing a skin or object surface sanitizer, an application of the pharmaceutical composition in preparing an air-atomizing sanitizer, an application of the pharmaceutical composition in preparing an oral cavity sanitizer, an application of the pharmaceutical composition in preparing a vaginal irrigation solution, or an application of the pharmaceutical composition in preparing vaginal gels. According to the chlorhexidine and oligochitosan-containing pharmaceutical composition, the oligochitosan plays a role in obviously improving the antibacterial action of the chlorhexidine.

The invention belongs to the field of biomedicine, and particularly relates to an egg yolk antibody of HPV E6 / E7 recombined minicircle DNA and application of the antibody in preparing a drug for treating HPV infection. The egg yolk antibody is obtained by utilizing HPV E6 / E7 recombined minicircle DNA as a nuclear acid antigen for direct immunization of a laying hen. The egg yolk antibody can be used for preparing the drug for treating HPV infection. The egg yolk antibody is prepared into freeze-dried powder and subjected to superfine grinding, after lipidosome encapsulating, a nano-liposome encapsulating the egg yolk antibody is prepared, the antibody enters cells in a transmembrane mode, the high-activity anti-HPV antibody is input to a patient with positive HPV, and E6 / E7 protein in an HPV virus inside the cells is directly neutralized. The antibody is combined with antibacterial active ingredients (antibacterial compounds or gynecologic inflammation pathogen specific antibodies) andacceptable pharmaceutical carriers to be prepared into vagina spraying agents, vagina washing liquor, vagina gels, vagina soft and hard capsules, vagina suppositories, vagina membranes, vagina tablets, effervescent tablets, ointment, creams and the like, and can also be prepared into lozenges, chewable tablets, chewing gums and the like for both male and female.

The invention belongs to the technical field of medicines, and discloses a medicine composition containing metronidazole. The medicine composition comprises metronidazole, carbomer 934, propylene glycol, a solubilizer, a pH regulator and a complexing agent. The invention also discloses another medicine composition containing metronidazole. Another medicine composition disclosed by the invention is prepared from the following components in parts by weight: 35-45 parts of metronidazole, 40-50 parts of carbomer 934, 100-120 parts of propylene glycol, a solubilizer and 15-20 parts of a pH regulator, namely sodium citrate and L-arginine. Tests indicate that vaginal gel prepared from the medicine composition has better safety and stability.

The invention relates to the technical field of preparation of colpitis medicines, and especially relates to a vaginal gel and a preparation method thereof in order to solve the technical problem of unsatisfactory bacteriostasis, lubrication and moisture retention effects of existing vaginal gel products. The vaginal gel mainly comprises sodium hyaluronate, vitamin E succinate modified hyaluronic acid, EGF (epidermal growth factors), vitamins C, calcium chloride, pentanediol, glycerin, Rhodicare and a buffer system adopting disodium hydrogen phosphate-citric acid as gel. The vaginal gel has anti-inflammatory activity, improves the wetness of vaginas, is used for treating vaginal inflammatory diseases and alleviating vaginal dryness or used as a human body lubricant, has a vaginal mucosa squamous cell layer restoration promoting effect, can improve vaginal mucosa layer thinning and restore small injuries in vaginas to recover the elasticity and the softness of the vaginal mucosa, and is suitable for colpitis and vagina dryness people.

The invention relates to a commonly used drug spermicide for contraception, in particular to biodegradable contraception gel with antibacterial effect, and belongs to an autonomous external contraceptive. On the basis of the biodegradable contraception gel, exact quantitative administration can be realized by virtue of a disposable long cylinder applicator. The antibacterial contraception gel is composed of a spermicide, biodegradable gel and water. The gel is specifically vaginal gel compounded by silk fibroin and chitosan and comprises the following components in mass concentration: 2-8% ofsilk fibroin, 0.5-2% of chitosan, 0.5-2% of carbomer 940 or hydroxypropyl methyl cellulose, 5-12% of glycerol and propylene glycol and the balance of water, and pH value is regulated to be 3.5-5. Theproduct can achieve the effects of rapidly killing sperms and carrying out contraception and birth control, also has antibacterial effect and can prevent and alleviate germ infection in genital tract.Ingredients of the gel are biodegradable, and degradation products can be absorbed and have the effect of alleviating vaginal dryness and atrophy to some extent. The gel preparation fills a needle tube type tool and can be directly injected deep inside a vagina, and the aim of the exact quantitative administration is achieved. The product has good biocompatibility, can not influence pH of the vagina, has no side effect and is worthy of being popularized and applied in clinic.

The invention relates to the technical field of preparation of medicines for treating vaginitis, particularly relates to a vaginal gel containing multi-effect factors and a preparation method thereof,and solves the technical problems that the antibacterial, lubricating and moisturizing effects of the existing vaginal gel products are not ideal. The vaginal gel contains a conditioned medium extracting solution of mesenchymal stem cells and traditional Chinese medicine extract, can effectively inhibit the propagation of vaginitis-related bacteria and improve the vaginal moistness, is used for treating vaginal inflammation and relieving vaginal dry symptoms or serves as a human body lubricant, simultaneously has the effect of promoting the repair of the squamous epithelial cell layer of thevaginal mucosa, can enable the vaginal mucosa layer to be thinned and repair small injuries in the vagina, can recover the elasticity of the vaginal mucosa and enable the vaginal mucosa to restore elasticity and softness, and is suitable for people suffering from vaginitis and colpoxerosis.

The invention discloses antibacterial moisturizing gel and a preparation method thereof. The antibacterial moisturizing gel comprises the following raw material ingredients in parts by weight: 0.1-2 parts of organic acid, 8-15 parts of a moisturizer, 2-4 parts of a nutrient agent and 85-87 parts of water. The invention solves the technical problems that vaginal gel in relevant technologies adoptsa silver ion antibacterial agent and easily results in heavy metal poisoning, and a broad-spectrum cation antibacterial agent and a Chinese patent medicine antibacterial medical material, as antibacterial ingredients, have a relatively poor antibacterial effect.

The invention discloses a vaginal gel for treating gynecological inflammation, and a preparation method thereof. The vaginal gel is prepared mainly by taking houttuynia volatile oil and honeysuckle total organic acids as effective components. Meanwhile, the invention also discloses a method for preparing the vaginal gel. The method ensures higher content of the effective components by extracting, enriching and purifying houttuynia and honeysuckle. The vaginal gel has the characteristics of convenient drug administration, good absorption and high efficacy.

A Chinese medicine in the form of soft-capsule, tablet, or capsule for preventing and treating vaginitis, pudendal itching, morbid leukorrhea, etc and preventing venereal disease is prepared from 7 Chinese-medicinal materials including rhubarb, hineysuckle flower, alum, borneol, etc. Its preparing process is also disclosed.

The invention relates to a method for preparing metronidazole vaginal gel. The method comprises the following steps that (1) edetate disodium is mixed with water, then carbomer 974P is added, the mixture is subjected to sufficient swelling and vacuum homogenous emulsification, and a gel substrate is obtained; (2) the pH value of the gel substrate is conditioned to be 4.0-4.5, and blank gel is obtained; and (3) methyl parahydroxybenzoate and propyl p-hydroxybenzoate are mixed at the mass ratio of (2 to 6) to 1 and added into propylene glycol, and a propylene glycol solution is obtained; the propylene glycol solution is mixed with water, metronidazole is added to be sufficiently dissolved, the mixture is sufficiently mixed with the blank gel, and the metronidazole vaginal gel is obtained. The method provided by the invention optimizes the preparation technology of the metronidazole vaginal gel, the adding order and the mixing mode of the raw materials, particularly carbomer 974P is adopted to replace carbomer 934P commonly applied in the prior art, the condition that the drug efficacy performance is not declined after the ingredient is replaced is ensured, and the safety is higher.

The invention provides a vagina gel for preventing dysmenorrhea and improving immunity of a private part in a menstrual period. The gel consists of a traditional Chinese medicine extract, glycerinum, carbomer 940, triethanolamine, methylisothiazolinone and deionized water. If the vagina gel for preventing dysmenorrhea and improving immunity of the private part in the menstrual period is used before the menstrual period, symptoms of dysmenorrhea can be relieved effectively, the immunity of the private part can be improved in the menstrual period of a woman, and good sterilizing and antibacterial effects can be achieved.

The invention relates to the technical field of antibody drugs, in particular to anti-HPV31L1 monoclonal neutralizing antibodies and application thereof. The invention provides the specific monoclonalneutralizing antibodies of HPV31 and a hybridoma cell line for producing the antibodies. One monoclonal neutralizing antibody with the highest neutralizing activity titer in the monoclonal neutralizing antibodies can be widely applied to infection detection of the HPV31 virus in clinical samples in virtue of an indirect ELISA method, a double-antibody sandwich ELISA method, an immune hybridization method and the like; the monoclonal neutralizing antibody with the highest neutralizing activity titer is used for preparing a vaginal gel, a vaginal cleaning fluid, an external lotion, a vaginal suppository, freeze-dried powder, a vaginal effervescent tablet and the like for treating HPV31 infected patients, and can effectively improve the clinical negative conversion rate of the HPV31 patients. The anti-HPV31L1 monoclonal neutralizing antibodies and the application thereof in the invention are of great significance to the healthy development of women and the prevention and control of public health.

The invention belongs to the technical field of medicines, and discloses a medicine composition containing palmatine. The medicine composition comprises palmatine, hydroxypropyl methylcellulose, ethylparaben and a pH regulator. The invention further discloses another medicine composition containing palmatine. The medicine composition comprises palmatine, hydroxypropyl methylcellulose, sorbic acid and L-glutamic acid. Tests indicate that vaginal gel prepared from the medicine composition has better safety and stability.

The invention belongs to the field of gynecological medicine preparation, and particularly relates to a preparation method of progesterone vaginal gel, which comprises: preparing a premix from active pharmaceutical ingredients progesterone and a polymer, adding into a water phase to obtain a hydrogel phase, adding a proper amount of a sodium hydroxide solution, and adjusting the pH value to 2.5-3.5 to obtain the progesterone vaginal gel. The progesterone vaginal gel can effectively solve the problems that in the progesterone vaginal gel preparation process, a polymer such as suspension gel swells quickly, and the content uniformity of raw material medicines is difficult to control, and meanwhile in-vitro dissolution is consistent with that of an original drug.

External vaginal gel for treating uterine fibroids is prepared from the following components in parts by weight: 0.5-15 parts of radix rehmanniae, 0.5-15 parts of radix salviae miltiorrhizae, 0.5-10 parts of safflower, 0.5-15 parts of fructus aurantii, 0.5-15 parts of radix bupleuri, 0.5-15 parts of curcuma aromatica, 0.5-15 parts of radix platycodonis, 0.5-15 parts of Szechuan lovage rhizome, 0.5-15 parts of angelica, 0.5-15 parts of achyranthes bidentata, 0.5-5 parts of cassia twig, 0.5-15 parts of poria cocos, 0.5-15 parts of tree peony bark, 0.5-15 parts of radix paeoniae rubra, 0.5-15 parts of prepared rehmannia root, 0.5-15 parts of radix scutellariae, 0.2-1 parts of rhizoma zingiberis (fried), 0.5-15 parts of corydalis tuber, 0.5-15 parts of epimedium, 0.5-15 parts of fructus evodiae, 0.5-15 parts of desertliving cistanche, 0.5-15 parts of wild chrysanthemum, 0.5-15 parts of fructus cnidii, 0.5-5 parts of foeniculum vulgare (fried), 0.5-15 parts of bletilla striata, 0.2-1 part of cinnamon, 0.5-5 parts of dried pinellia tuber, 0.5-5 parts of dwarf lilyturf turber, 0.5-15 parts of angelica, 0.5-5 parts of peach kernels, 0.5-5 parts of panax ginseng, 0.5-15 parts of curcuma aromatica salisb, 0.5-15 parts of sparganium stoloniferum, 0.1-0.5 part of mugwort leaf oil, 0.5-5 parts of cattail pollen, 0.5-5 parts of trichosanthes root, 0.2-1 part of donkey-hide gelatin, 0.5-5 parts of acid, 0.5-5 parts of alkali, 3-20 parts of a surfactant, 0.1-5 parts a compound preservative, 0.01-2 parts a pH adjusting agent and 0.2-10 parts of a thickening agent. The external vaginal gel can effectively activate blood to promote menstruation, and prevent and cure uterine fibroids.

The invention discloses a policresulen sulfonamide-formaldehyde vaginal gel, which is characterized in that the invention comprises the following components: policresulen sulfonamide-formaldehyde, Carbopol, PEG, propanediol, polysorbate, ethyl hydroxy benzoate, EDTA-2Na, trolamine, ethanol and distilled water. The invention has little acrimony, without foreign body sensation for sufferers, and is easily accepted by sufferers with rapid effect.

A matrine vagina gel is prepared from matrine (5-50 wt. portions) Kapomu (5-50), glycerine (25-500) and distilled water (400-4500). Its advantages are high curative effect, long stay time, no damage to vagina and no pollution to clothes.

The invention relates a vagina gel preparation and a preparation method thereof. The vagina gel preparation comprises a carrier and a gene used for treatment. The vagina gel preparation also compriseshydrophilic high polymer material modified montmorillonite, and the carrier comprises a cationic polymer. The vagina gel preparation can favorably stabilize the structure of a nanoparticle, and has high transfection efficiency, a good treatment effect and high safety, and can be locally applied through the vagina. The vagina gel preparation has a simple preparation process and a flexible reagentformula.

The invention discloses a quality control method for women's washing lotion and its derivating agents including bougie, vaginal gelling agent, vaginal tablet and effervescent tablet, characterized in that a process of thin-layer authentication for pomegranate bark and borneo camphor is added, and a high performance liquid phase chromatographic method is employed to control the quality of the medicament.

The invention relates to a miconazole nitrate-chitosan sustained-release vaginal gel and a preparation method thereof. The miconazole nitrate-chitosan sustained-release vaginal gel comprises miconazole nitrate, chitosan, polycarbophil, glycerin, glyceryl behenate, sodium benzoate, triethanolamine, an acetic acid solution with a mass fraction of 2% and injection water. The method comprises the following steps: preparation of a chitosan-acetic acid sohution; preparation of a polymer phase; preparation of an oil phase; preparation of a water phase; and preparation of a sustained-release capsule. According to the invention, good linear relation is obtained in a range of 0.050 to 0.80 mg / ml; an average recovery rate is 97.91% (wherein RSD is equal to 0.24%); within-day and day-to-day precision tests are carried out, and test results show that within-day precision and day-to-day precision are good; the prepared miconazole nitrate-chitosan sustained-release vaginal gel has accumulative release rates of 35.54%, 56.02% and 93.92% in 1 h, 2 h and 12 h, respecitively; and clinical data shows that the sustained-release vaginal gel has an effective rate of 95.83% in treatment of monilial vaginitis.

A vaginal gel tablet for treating gynopathy contains hydrophilic gel material (1-40%) and effevescent disintegrant or superdisintegrant (20-50%). It advantages are quickly taking its effect and durable action.

The invention belongs to the technical field of medicines, and discloses a medicine composition containing palmatine. The medicine composition comprises palmatine, hydroxypropyl methylcellulose, ethylparaben and a pH regulator. The invention further discloses another medicine composition containing palmatine. The medicine composition comprises palmatine, hydroxypropyl methylcellulose, sorbic acid and L-glutamic acid. Tests indicate that vaginal gel prepared from the medicine composition has better safety and stability.

The invention discloses an application of keratinocyte growth factor-2 in the preparation of medicine for treating chronic cervicitis. The keratinocyte growth factor-2 is used as an active ingredient to prepare vaginal suppositories, vaginal effervescent tablets, vaginal gels and other vaginal administration dosage forms. The obtained medicine has good anti-inflammation effect on chronic cervicitis, promotes the repair of cervical epithelium, and has the advantages of simple operation, good effect and no toxic or side effect.

The invention discloses a composition, vaginal gel prepared from the composition and application of the composition in resisting human papilloma viruses. The gel comprises the effective components ofbeta-glucan and hyaluronic acid, and the beta-glucan and hyaluronic acid are both carriers of gel products and are anti-human papilloma virus functional components of the gel products. And moreover, the the beta-glucan and hyaluronic acid have quite high biocompatibility and almost have no toxic or side effect. The beta-glucan and hyaluronic acid have the effect of synergistically resisting humanpapilloma viruses, and have the advantages of being stable, moderate in viscosity, comfortable to use and free of influence on vaginal bacteria.